Biologics Company Profile

Biologics is a specialty oncology pharmacy thoughtfully changing the way cancer drugs are dispensed to cancer patients through its Specialty Pharmacy; Clinical Trial Drug Management; Wholesale; Pharmaceutical Product Launch; and Veterinary services.
Founded in 1994, Biologics has carved a niche for itself in the $16 billion* specialty pharmacy industry as the first and only specialty pharmacy to dispense only oncology drugs. Biologics stocks only drugs that are currently used to treat cancer or are prescribed as supportive medications to I.V.-administered chemotherapy including subcutaneously injected, oral chemotherapeutic and anti-emetic drugs.
These specialty drugs require a high level of pharmaceutical expertise as they have unique storage, handling and dispensing standards. Biologics accompanies its exceptional pharmacy service with a dose of patient advocacy including insurance and Medicare filing, customized dispensing and packaging, on-time home delivery, and clinical monitoring for compliance and side effects. Privately held, Biologics is located in Raleigh, N.C
Location
625 Oberlin RoadPO Box 10568
Raleigh
North Carolina
27605
United States of America
Contact
Phone: 919-546-9810
Fax: 919-546-9816
Email: info@biologicstoday.com
News Articles
Spinnovation launches biologics analysis division
Spinnovation Biologics to provide profiling and characterisation of biologics
Biologics Contracting Demand Drives Cytovance Expansion
Cytovance Biologics is once again expanding its manufacturing capabilities as CMOs compete to keep up with pharma’s growth rate in biologics.
Genedata Biologics 3.0 Boosts Efficiency Through Standardization
Palm Springs, Calif. (PRWEB) January 21, 2013 Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced the release of Genedata Biol...
ROCKVILLE, Md., April 4, 2013 /PRNewswire/ --Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of synthetic biologics and innovative medicines for serious infections and diseases, announced t...
Cobra Biologics and Algeta Sign Agreement to Manufacture Monoclonal Antibody (News)
Cobra Biologics Ltd, the international clinical and commercial contract manufacturer of biologics and pharmaceuticals and Algeta ASA, a company focused on the development of novel targeted cancer ...
Synthetic Biologics raises $10.8M financing
Synthetic Biologics, an Ann Arbor, Mich.-based biotech that develops of synthetic biologics and innovative medicines for serious diseases and unmet medical needs, has entered into definitive stock pu...
Synthetic Biologics to raise $10.9 million
Synthetic Biologics Inc. (NYSE-M:SYN) said it plans to raise about $10.9 million through the sale of 6.8 million shares at $1.60 in a private placement to new and existing investors. The price is a 31...
Synthetic Biologics raises $10.8 million
Synthetic Biologics Inc. (NYSE-M:SYN) raised about $10.8 million on Wednesday through the sale of about 6.8 million shares at $1.60 in a private placement to new and existing investors. The price is a...
Drugs and Medications
Standardized cat pelt [Jubilant HollisterStier LLC]
ALLERGENIC EXTRACT STANDARDIZED CAT PELT AP ACETONE PRECIPITATED
Standardized cat hair [Jubilant HollisterStier LLC]
ALLERGENIC EXTRACT STANDARDIZED CAT HAIR AP Acetone Precipitated
Cinryze [ViroPharma Biologics]
These highlights do not include all the information needed to use CINRYZEâ„¢ safely and effectively. See full prescribing information for CINRYZE.CINRYZEâ„¢ (C1 Esterase Inhibitor [Human]) For Intrave...
PubMed Articles
OBJECTIVE: To investigate the influence of biologics on mortality and risk factors for death in rheumatoid arthritis (RA) patients. METHODS: RA patients treated with at least one dose of biologics in...
Clinical pharmacology considerations in biologics development.
Biologics, including monoclonal antibodies (mAbs) and other therapeutic proteins such as cytokines and growth hormones, have unique characteristics compared to small molecules. This paper starts from...
Challenges and approaches for the development of safer immunomodulatory biologics.
Immunomodulatory biologics, which render their therapeutic effects by modulating or harnessing immune responses, have proven their therapeutic utility in several complex conditions including cancer an...
Strategies for non-invasive delivery of biologics.
Macromolecular therapeutics, in particular, many biologics, is the most advancing category of drugs over conventional chemical drugs. The potency and specificity of the biologics for curing certain di...
Pharmacological Approaches in Immuno-rhumatology.
Biologics have proven to be an effective treatment option for adults with rheumatoid arthritis but their use in clinical practice may be limited by concerns over severe side effect...
Clinical Trials
Ustekinumab Safety and Surveillance Program Using the Ingenix NHI Database
The patients included in this observational study will be drawn from a research database containing claims and enrollment data for members of a large, geographically diverse US health plan...
Golimumab Safety and Surveillance Program Using the Ingenix NHI Database
The participants included in this observational study will be drawn from a research database containing claims and enrollment data for members of a large, geographically diverse US health...
Retrospective Evaluation of the Radiographic Efficacy of Conventional and Biologic Treatment
This study involves review and analysis of disease activity in patients with rheumatoid arthritis who where treated with either conventional DMARDs (Disease Modifying Antirheumatic Drugs)...
Positron Emission Tomography in Rheumatoid Arthritis With Adalimumab (PETRA)
Biologics are routinely used for the treatment of rheumatoid arthritis (RA). Adalimumab is a human monoclonal antibody that inhibit the Tumor Necrosis Factor alpha (TNF-alpha). Identificat...
Study of KB003 In Biologics-Inadequate Rheumatoid Arthritis
The purpose of this study is to evaluate the safety, pharmacokinetics, and efficacy of various repeat-dose regimens of KB003 in subjects with active Rheumatoid Arthritis (RA) who have had...
Companies
Avecia Biologics was acquired in February 2010 by MSD, the UK subsidiary of Merck & Co Inc, the world’s second largest pharmaceutical company. MSD Billingham is one of the world's leading contract...
Permeon Biologics is pioneering a breakthrough class of intracellular biologics that target a broad spectrum of previously undruggable targets. Leveraging its novel IntraphilinâÂ...
CMC Biologics (www.cmcbio.com) is a leading contract development and manufacturing organization that provides fully integrated biopharmaceutical development and manufacturing services to clients aroun...
Cascade Biologics Incorporated
Cascade Biologics, Inc. cells, media, growth supplements and reagents for biomedical research.
Biologics is a specialty oncology pharmacy thoughtfully changing the way cancer drugs are dispensed to cancer patients through its Specialty Pharmacy; Clinical Trial Drug Management; Wholesale; Pharma...
More Information about "Biologics" on BioPortfolio
We have published hundreds of Biologics news stories on BioPortfolio along with dozens of Biologics Clinical Trials and PubMed Articles about Biologics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Biologics Companies in our database. You can also find out about relevant Biologics Drugs and Medications on this site too.